Javascript must be enabled to continue!
COMPARISON THE EFFECTIVENESS OF SITAGLIPTIN VERSUS SULFONYLUREA FOR MANAGEMENT OF PATIENTS WITH TYPE II DIABETES MELLITUS
View through CrossRef
Background: Type 2 diabetes mellitus (T2DM) is characterized by prolonged hyperinsulinemia, insulin resistance, and progressive hyperglycemia. Current guidelines for treating patients with T2DM are based on glycemic standards. Sitagliptin seems to maintain its positive effects on glycemia and fasting plasma insulin on the long term as compared to sulfonylurea.
Objective: To compare the effectiveness of sitagliptin versus sulfonylurea for management of patients with type II diabetes mellitus
Methods: it was randomized controlled trial. The data was collected in North medical ward, department of medicine Mayo hospital Lahore. The patients were randomly divided into two groups e.g Group A Sitagliptin and group B sulfonylurea. The blood sample were drawn at baseline and after 12 weeks for HbA1c level.
Results: In Sitagliptin group, the mean age of patients was 57.93±13.10years. In sulfonylurea group, the mean age of patients was 63.51±11.23years. There were 35 (50.0%) male and 35 (50.0%) females in Sitagliptin group. There were 31 (44.3%) male and 39 (55.7%) females in sulfonylurea group. There was 1.19±1.00% decrease in HbA1c with sitagliptin and 0.53±0.31% with sulfonylurea. The difference was significant (p<0.05). In our trial, effectiveness was achieved in 50 (71.4%) with sitagliptin while in 33 (47.1%) with sulfonylurea. The difference was significant (p<0.05).
Conclusion: Thus, Sitagliptin is more effective and control more HbA1c than sulfonylurea for management of T2DM
Postgraduate Medical Institute, Lahore General Hospital
Title: COMPARISON THE EFFECTIVENESS OF SITAGLIPTIN VERSUS SULFONYLUREA FOR MANAGEMENT OF PATIENTS WITH TYPE II DIABETES MELLITUS
Description:
Background: Type 2 diabetes mellitus (T2DM) is characterized by prolonged hyperinsulinemia, insulin resistance, and progressive hyperglycemia.
Current guidelines for treating patients with T2DM are based on glycemic standards.
Sitagliptin seems to maintain its positive effects on glycemia and fasting plasma insulin on the long term as compared to sulfonylurea.
Objective: To compare the effectiveness of sitagliptin versus sulfonylurea for management of patients with type II diabetes mellitus
Methods: it was randomized controlled trial.
The data was collected in North medical ward, department of medicine Mayo hospital Lahore.
The patients were randomly divided into two groups e.
g Group A Sitagliptin and group B sulfonylurea.
The blood sample were drawn at baseline and after 12 weeks for HbA1c level.
Results: In Sitagliptin group, the mean age of patients was 57.
93±13.
10years.
In sulfonylurea group, the mean age of patients was 63.
51±11.
23years.
There were 35 (50.
0%) male and 35 (50.
0%) females in Sitagliptin group.
There were 31 (44.
3%) male and 39 (55.
7%) females in sulfonylurea group.
There was 1.
19±1.
00% decrease in HbA1c with sitagliptin and 0.
53±0.
31% with sulfonylurea.
The difference was significant (p<0.
05).
In our trial, effectiveness was achieved in 50 (71.
4%) with sitagliptin while in 33 (47.
1%) with sulfonylurea.
The difference was significant (p<0.
05).
Conclusion: Thus, Sitagliptin is more effective and control more HbA1c than sulfonylurea for management of T2DM.
Related Results
Hypertension and Type 2 Diabetes Are Associated With Decreased Inhibition of Dipeptidyl Peptidase-4 by Sitagliptin
Hypertension and Type 2 Diabetes Are Associated With Decreased Inhibition of Dipeptidyl Peptidase-4 by Sitagliptin
Abstract
Context
Patients with diabetes often have comorbidities such as hypertension. It is not known how individual characteri...
Unveiling the Differential Impact of Clarithromycin and Metronidazole on the Incretin Effect of Sitagliptin
Unveiling the Differential Impact of Clarithromycin and Metronidazole on the Incretin Effect of Sitagliptin
Background: Sitagliptin is a commonly used drug for the treatment of type 2 diabetes. Studies show that diabetic patients are at high risk of suffering severe complications after a...
PENURUNAN KADAR GULA DARAH DAN RESIKO ULKUS PADA PENDERITA DIABETES MELLITUS DENGAN SENAM KAKI DIABETES
PENURUNAN KADAR GULA DARAH DAN RESIKO ULKUS PADA PENDERITA DIABETES MELLITUS DENGAN SENAM KAKI DIABETES
ABSTRAKDiabetes mellitus adalah suatu penyakit dengan peningkatan glukosa darah di atas normal. Indonesia merupakan negara menempati urutan ke 7 dengan penderita diabetes mellitus ...
Analysis of coping type II diabetes mellitus
Analysis of coping type II diabetes mellitus
Diabetes mellitus is a chronic disease that is a major health and social problem worldwide. This study aims to assess the coping process of patients with type II Diabetes Mellitus ...
Combination Therapy with a Dipeptidyl peptidase-4 Inhibitor, Sulfonylurea, and Metformin Markedly Improves HbA1c Levels in Japanese Patients with Type 2 Diabetes Mellitus
Combination Therapy with a Dipeptidyl peptidase-4 Inhibitor, Sulfonylurea, and Metformin Markedly Improves HbA1c Levels in Japanese Patients with Type 2 Diabetes Mellitus
Combination therapy with a dipeptidyl peptidase (DPP)-4 inhibitor and metformin or sulfonylurea results in substantial and additive glucose-lowering effects in patients with type 2...
Undiagnosed Diabetes in Acute Coronary Syndrome: A Silent Threat in Pakistan
Undiagnosed Diabetes in Acute Coronary Syndrome: A Silent Threat in Pakistan
Diabetes mellitus (DM) has emerged as one of the most pressing public health challenges globally, and Pakistan stands among the countries most severely affected. With rising urbani...
Dipeptidyl Peptidase‐4 Inhibition Potentiates Stimulated Growth Hormone Secretion and Vasodilation in Women
Dipeptidyl Peptidase‐4 Inhibition Potentiates Stimulated Growth Hormone Secretion and Vasodilation in Women
Background
Diminished growth hormone (
GH
) is associated with impaired endothelial function and fibrinolysis.
...
Glimepiride Strongly Enhances the Glucose-Lowering Effect in Triple Oral Antidiabetes Therapy with Sitagliptin and Metformin for Japanese Patients with Type 2 Diabetes Mellitus
Glimepiride Strongly Enhances the Glucose-Lowering Effect in Triple Oral Antidiabetes Therapy with Sitagliptin and Metformin for Japanese Patients with Type 2 Diabetes Mellitus
Background:
After approval of sitagliptin and >750 mg of metformin in Japan, a triple oral antidiabetes drug (OAD) regimen including sulfonylurea, metformin,...

